Publications by authors named "Marta Erro Iribarren"
Article Synopsis
- The study investigates the safety and effectiveness of sotrovimab for treating severe COVID-19 in immunocompromised patients, specifically looking at data from October to December 2021.
- Out of 32 patients studied, most were either organ transplant recipients or had blood cancers, with some experiencing respiratory issues and a small percentage dying or needing ventilation.
- Results suggest that early treatment within the first two weeks may lead to better outcomes, and no adverse effects were reported from sotrovimab, indicating it could be a safe option that requires further research.
The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination.
View Article and Find Full Text PDFIntroduction: In recent years an increase in the prevalence of colonization and infection by Scedosporium spp. in patients with cystic fibrosis (CF) has been observed. In this article, we study the frequency of isolation of Scedosporium spp.
View Article and Find Full Text PDF